Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2026
First-line Anlotinib plus Anthracyclines and Ifosfamide Followed by Anlotinib Maintenance in Advanced Soft-Tissue Sarcoma: A Phase II Single-Arm Trial.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A rare case of relapsed primary pulmonary synovial sarcoma (PPSS) following surgery with multidisciplinary team management: case report and systematic review of literature.Journal of cardiothoracic surgery · 2026Pooled it
- Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2- breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation.Signal transduction and targeted therapy · 2026Trial
- Metastatic malignant phyllodes tumor of the breast with rapid progression and subsequent response to immunotherapy: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
purposeThis study evaluated the efficacy and safety of first-line anlotinib combined with anthracyclines and ifosfamide, followed by anlotinib maintenance therapy, in patients with advanced soft-tissue sarcoma. PATIENTS AND
methodsPatients received four to six cycles of combination therapy administered every 21 days, comprising anlotinib (12 mg orally daily on days 1-14), anthracyclines (epirubicin 40 mg/m2 daily on days 1-2 or liposomal doxorubicin 30 mg/m2 on day 1), and ifosfamide (2 g/m2 daily on days 1-3). Following induction therapy, patients without disease progression continued anlotinib maintenance until progression, unacceptable toxicity, or death. The primary endpoint was the objective response rate. Secondary endpoints included the disease control rate, progression-free survival, overall survival, and adverse events (AE). The study was registered at the Chinese Clinical Trial Registry (ChiCTR2100054711).
resultsA total of 52 patients were enrolled. The objective response rate was 30.8% [95% confidence interval (CI), 18.7%-45.1%], and the disease control rate was 82.7% (95% CI, 69.7%-91.8%). With a median follow-up of 29.9 months (95% CI, 24.6-32.3), the median progression-free survival was 6.2 months (95% CI, 2.6-11.2). The median overall survival was not reached (95% CI, 14.4-not estimable). Treatment-related AE of any grade occurred in all patients. The most frequently reported AE included nausea (100%), fatigue (86.5%), and hypoalbuminemia (44.2%). The most common grade 3 to 4 AE included anemia (23.1%), leukopenia (17.3%), and thrombocytopenia (9.6%). No treatment-related deaths occurred.
conclusionsFirst-line anlotinib combined with anthracyclines and ifosfamide, followed by anlotinib maintenance, demonstrated encouraging efficacy with acceptable toxicities in patients with advanced soft-tissue sarcoma, warranting further investigation in randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.